Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.

MLA

Zago, Manola, et al. “Classical Hodgkin Lymphoma as de Novo B-Cell Malignancy after Treatment of Multiple Myeloma in the Pre-Lenalidomide Era.” Clinical Lymphoma, Myeloma & Leukemia, vol. 14, no. 1, Feb. 2014, pp. e7–11. EBSCOhost, https://doi.org/10.1016/j.clml.2013.07.101.

APA

Zago, M., Adam, P., Goldschmidt, H., Fend, F., Kanz, L., & Weisel, K. (2014). Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era. Clinical Lymphoma, Myeloma & Leukemia, 14(1), e7–e11. https://doi.org/10.1016/j.clml.2013.07.101

Chicago

Zago, Manola, Patrick Adam, Hartmut Goldschmidt, Falko Fend, Lothar Kanz, and Katja Weisel. 2014. “Classical Hodgkin Lymphoma as de Novo B-Cell Malignancy after Treatment of Multiple Myeloma in the Pre-Lenalidomide Era.” Clinical Lymphoma, Myeloma & Leukemia 14 (1): e7–11. doi:10.1016/j.clml.2013.07.101.